Zoledronic and Embolex drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Zoledronic (zoledronic acid) and Embolex (dihydroergotamine mesylate; heparin sodium; lidocaine hydrochloride). Common drug interactions include necrosis among females and malignant neoplasm progression among males.

The phase IV clinical study analyzes what interactions people have when they take Zoledronic and Embolex. It is created by eHealthMe based on reports of 11 people who take the same drugs from the FDA, and is updated regularly.

What is Zoledronic?

Zoledronic has active ingredients of zoledronic acid. eHealthMe is studying from 29,812 Zoledronic users. Check the latest studies of Zoledronic.

What is Embolex?

Embolex has active ingredients of dihydroergotamine mesylate; heparin sodium; lidocaine hydrochloride. eHealthMe is studying from 1,161 Embolex users. Check the latest studies of Embolex.

On Jul, 20, 2026

11 people who take Zoledronic and Embolex together, and have interactions are studied.

Zoledronic and Embolex drug interactions.

What are the common drug interactions of Zoledronic and Embolex, by gender? *:

female:

Necrosis (the death of body tissue)
Subcutaneous abscess
Asthenia (weakness)
Diarrhoea
Hair colour changes
Malignant neoplasm progression (cancer tumour came back)
Metastatic renal cell carcinoma (spreadable kidney cell tumour)
Pain in extremity
Pneumonia

male:

Malignant neoplasm progression (cancer tumour came back)
Metastases to spine (cancer spreads to spine)
Thrombocytopenia (decrease of platelets in blood)
Metastatic malignant melanoma (spreadable cancer tumour of melanine)
Spinal fracture (fracture in one of vertebrae)
Cholecystitis (infection of gallbladder)
Hepatitis (inflammation of the liver)
Metastases to meninges (cancer spreads to meninges)
Non-small cell lung cancer metastatic (type of epithelial lung cancer spreads to other parts)
Oesophageal candidiasis (fungal infection of oesophagus)

What are the common drug interactions of Zoledronic and Embolex, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

Diarrhoea
Hair colour changes
Malignant neoplasm progression (cancer tumour came back)
Metastatic renal cell carcinoma (spreadable kidney cell tumour)
Pain in extremity
Pneumonia
Non-small cell lung cancer metastatic (type of epithelial lung cancer spreads to other parts)
Pathological fracture (broken bone caused by disease)
Asthenia (weakness)

60+:

Malignant neoplasm progression (cancer tumour came back)
Metastases to spine (cancer spreads to spine)
Metastatic malignant melanoma (spreadable cancer tumour of melanine)
Spinal fracture (fracture in one of vertebrae)
Cholecystitis (infection of gallbladder)
Hepatitis (inflammation of the liver)
Metastases to meninges (cancer spreads to meninges)
Oesophageal candidiasis (fungal infection of oesophagus)
Thrombocytopenia (decrease of platelets in blood)

What are the existing conditions these people have? *

Metastatic Malignant Melanoma (spreadable cancer tumour of melanine): 4 people, 36.36%
Malignant Melanoma (skin cancer rises from melancytes): 4 people, 36.36%
High Blood Pressure: 3 people, 27.27%
Breast Cancer: 3 people, 27.27%
Pain: 3 people, 27.27%
Multiple Myeloma (cancer of the plasma cells): 2 people, 18.18%
Osteolysis (dissolution of bone): 2 people, 18.18%
Deep Venous Thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis): 2 people, 18.18%
Neuralgia (pain in one or more nerves): 1 person, 9.09%
Nausea (feeling of having an urge to vomit): 1 person, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Zoledronic and Embolex?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously